NCT02555657 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 312
- group Id
- BG001
- value
- 310
- group Id
- BG002
- value
- 622
- units
- Participants
- groups
- description
- Participants received pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years). Qualified participants who received first course of pembrolizumab but continued to experience disease progression may have, at investigator's discretion, initiated a second course of pembrolizumab at 200 mg IV Q3W for up to 17 administrations (up to \~1 year).
- id
- BG000
- title
- Pembrolizumab
- description
- Participants received capecitabine, eribulin, gemcitabine, or vinorelbine as single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice, TPC) in accordance with local regulations and guidelines.
- id
- BG001
- title
- Chemotherapy
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 11.4
- value
- 51.4
- group Id
- BG001
- spread
- 11.2
- value
- 52.6
- group Id
- BG002
- spread
- 11.3
- value
- 52.0
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 312
- group Id
- BG001
- value
- 308
- group Id
- BG002
- value
- 620
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 8
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 87
- group Id
- BG001
- value
- 101
- group Id
- BG002
- value
- 188
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 17
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 183
- group Id
- BG001
- value
- 180
- group Id
- BG002
- value
- 363
- title
- White
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 24
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 22
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 312
- group Id
- BG001
- value
- 310
- group Id
- BG002
- value
- 622
- units
- Participants
- groups
- description
- Participants received pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years). Qualified participants who received first course of pembrolizumab but continued to experience disease progression may have, at investigator's discretion, initiated a second course of pembrolizumab at 200 mg IV Q3W for up to 17 administrations (up to \~1 year).
- id
- BG000
- title
- Pembrolizumab
- description
- Participants received capecitabine, eribulin, gemcitabine, or vinorelbine as single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice, TPC) in accordance with local regulations and guidelines.
- id
- BG001
- title
- Chemotherapy
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 11.4
- value
- 51.4
- group Id
- BG001
- spread
- 11.2
- value
- 52.6
- group Id
- BG002
- spread
- 11.3
- value
- 52.0
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 312
- group Id
- BG001
- value
- 308
- group Id
- BG002
- value
- 620
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 8
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 87
- group Id
- BG001
- value
- 101
- group Id
- BG002
- value
- 188
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 17
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 183
- group Id
- BG001
- value
- 180
- group Id
- BG002
- value
- 363
- title
- White
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 24
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 22
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle